Exchange Traded Concepts LLC Has $1.51 Million Position in Zoetis Inc. $ZTS

Exchange Traded Concepts LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 55.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,994 shares of the company’s stock after acquiring an additional 4,266 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Zoetis were worth $1,509,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Halbert Hargrove Global Advisors LLC increased its stake in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the 3rd quarter worth about $31,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund bought a new stake in Zoetis in the 4th quarter valued at about $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on ZTS. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Morgan Stanley set a $160.00 target price on Zoetis in a report on Thursday, December 18th. UBS Group set a $136.00 price target on shares of Zoetis in a research report on Thursday, January 29th. Barclays began coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Stock Down 0.6%

Zoetis stock opened at $117.45 on Thursday. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The stock has a market cap of $49.58 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The firm’s 50-day simple moving average is $122.97 and its 200 day simple moving average is $128.49. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the business posted $1.40 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.